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COVID-19 and Acute Esophageal Obstruction Management in the Emergency 
Department: An U.S. multicenter research network propensity-matched analysis 
Abstract 
Introduction- The Coronavirus Disease-2019 (COVID-19) caused by the novel SARS-CoV-2 led to 
significant strain on the Emergency Department (ED) visits worldwide. Multiple stay-at-home 
orders were issued during the pandemic unless medical treatment was urgently needed1. Acute 
esophageal obstruction (AEO) due to food/ foreign body impaction usually present to the ED, 
given its severe symptoms. Most esophageal foreign bodies pass through the gastrointestinal (GI) 
tract uneventfully, and related mortality is very low. Still, most of these patients receive 
endoscopic interventions (up to 76%)2. The number of non-urgent endoscopies plummeted 
sharply during the pandemic to reduce exposure and preserve personal protective equipment. It 
is unclear if ED visits for AEO and their endoscopic management changed due to the COVID-19 
pandemic in the United States (US).  
Methods- We utilized a federated cloud-based network database named TriNetX, which provides 
access to electronic medical records from 92 healthcare organizations from the US. The AEO adult 
patients hospitalized from January 1, 2020, to December 1, 2020, were compared to a similar 
timeline in 2019 from TriNetX. We used ICD-10 codes for food/foreign body in esophagus, causing 
other injury acute food impaction (T18.128 A, T18.12), foreign body esophagus (T18.198, T18.1, 
T18.19, T18.108, T18.108A). Outcomes of the study included utilization rates of 
esophagogastroduodenoscopy (EGD), esophageal perforation, inpatient hospitalization, and 
mortality. The outcomes were measured before and after 1:1 propensity matching of the groups 
based on the baseline demographics and comorbidities. 
Results- Prevalence of AEO among all ED visits in 2020 were 0.12% (5890 AEO ED visits among 
4,672,024 total visits), compared to 0.17% (23,478 AEO ED visits among 14,199,648 total visits) 
in 2019. There was a small but significant decrease (0.05%) in AEO ED visits from pre-pandemic 
compared to pandemic times (P<0.01). Patient with AEO had higher prevalence of eosinophilic 




[7.9%] vs. 1659 [7.1%], p=0.03) in 2020 group vs. 2019 group. Patients in the 2020-group had a 
lower EGD utilization (RR 0.63,95%CI:0.58–0.67, p<0.001) but esophageal perforation (RR 
0.87,95%CI:0.41–1.82) and inpatient hospitalization rates (RR 0.92,95%CI:0.79-1.05) did not 
differ between two groups. Interestingly, during the pandemic, the AEO patients had a lower 
mortality rate (RR 0.23, 95%CI:0.17–0.31, p<0.001) than in 2019.  
Conclusion-  
With the advent of COVID-19, multiple stay-at-home orders were issued in the US, with 
widespread healthcare services and utilization disruption. Patients have expressed concerns 
about visiting healthcare facilities due to the potential of the spread of SARS-CoV-23. Many GI 
societies also recommended deferring elective procedures. This was due to a concern for 
potential transmission of the virus from aerosolization of GI secretions and judicious use of PPE, 
which resulted in an overall reduction in the number of endoscopies during the pandemic4.  
Our study shows a small reduction (0.05%) of AEO ED visits in 2020 compared to 2019. However, 
EGD utilization plummeted to 63% for AEO in 2020. If this is due to spontaneous resolution of the 
food impaction or reduced presentations to the ED needs to be studied prospectively.  
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Table 1: Baseline characteristics, laboratory findings and clinical outcomes of the patients with Acute 
Esophageal Obstruction (AEO) ingestion during the COVID-19 pandemic (2020) when compared with pre-






Table 1: Baseline characteristics, laboratory findings and clinical outcomes of the patients with Acute Esophageal Obstruction (AEO) ingestion 
during the COVID-19 pandemic (2020) when compared with pre-COVID time (2019) € 
 
 
Before Propensity Score Matching After Propensity Score Matching 
AEO 2020  




AEO 2020  
N= 5886 (%) 
AEO 2019 
N= 5886 (%) 
P-Value 
Demographics 
Mean + S.D or n 
(%) 
Mean + S.D or n 
(%) 
 Mean + S.D or n (%) 
Mean + S.D or 
n (%) 
 
Age (Years) 59.42 (19.26) 60.28 (19.23) 0.002 59.42 (19.26) 59.92 (19.34) 0.162 
Female 2483 (42.16) 9869 (42.04) 0.866 2482 (42.17) 2475 (42.05) 0.896 
Race       
White 1264 (21.46) 4943 (21.05) 0.495 1262 (21.44) 1266 (21.51) 0.928 




3195 (54.24) 12823 (54.62) 0.608 3193 (54.25) 3194 (54.26) 0.985 
Diabetes mellitus 1322 (22.45) 5353 (22.8) 0.561 1321 (22.44) 1304 (22.15) 0.707 
Chronic lower respiratory 
diseases 
974 (16.54) 3834 (16.33) 0.702 972 (16.51) 970 (16.48) 0.960 
Chronic kidney disease (CKD) 739 (12.55) 2895 (12.33) 0.653 737 (12.52) 730 (12.4) 0.845 
Overweight and obesity 1340 (22.75) 4959 (21.12) 0.006 1337 (22.72) 1351 (22.95) 0.759 
Table 1
Ischemic Heart Disease 1300 (22.07) 5124 (21.83) 0.682 1300 (22.09) 1302 (22.12) 0.965 
Alcohol related disorders 465 (7.9) 1659 (7.07) 0.028 463 (7.87) 462 (7.85) 0.973 
Eosinophilic esophagitis 270 (4.58) 885 (3.77) 0.004 267 (4.54) 259 (4.4) 0.721 
Gastrointestinal hemorrhage 244 (4.14) 1032 (4.4) 0.394 244 (4.15) 278 (4.72) 0.128 
Psychotic disorders 245 (4.16) 921 (3.92) 0.405 244 (4.15) 232 (3.94) 0.574 
Clinical Presentation 
Nausea and Vomiting 1370 (23.26) 5220 (22.23) 0.091 1367 (23.23) 1338 (22.73) 0.525 
Abdominal Pain 2249 (38.18) 8413 (35.83) 0.001 2245 (38.14) 2118 (35.98) 0.015 
Medications 
Antiemetics 1294 (21.97) 4550 (19.38) <0.001 1292 (21.95) 1122 (19.06) 0.000 
Omeprazole 1164 (19.76) 4492 (19.13) 0.273 1160 (19.71) 1151 (19.56) 0.835 
Pantoprazole 848 (14.4) 3010 (12.82) 0.001 847 (14.39) 762 (12.95) 0.023 
H2 Blockers 420 (7.13) 1382 (5.89) 0.000 419 (7.12) 350 (5.95) 0.010 
Laboratory Findings After COVID-19 diagnosis 
Hemoglobin (g/dL) 13.57(1.99) 13.17(1.91) <0.001 13.48(1.96) 13.46(1.74) 0.837 
Platelets (109/L) 263.53(74.96) 239.97(76.9) <0.001 265.02(79.27) 243.88(78.77) <0.001 
Creatinine (mg/dL) 0.99 (0.52) 1.68 (8.51) 0.211 0.99 (0.52) 1.53 (6.94) 0.226 
Urea nitrogen (mmol /L) 16.9 (8.27) 16.87 (8.48) 0.966 16.88 (8.28) 16.33 (8.22) 0.486 
Chloride (mEq/L) 103.24 (3.38) 103.27 (3.6) 0.934 103.3 (3.27) 103.11 (3.71) 0.550 
Bicarbonate (mEq/L) 26.44 (3.07) 26.5 (3.25) 0.811 26.44 (3.08) 26.52 (3.11) 0.786 
Potassium (mEq/L) 4.32 (0.43) 4.32 (0.45) 0.871 4.32 (0.43) 4.33 (0.56) 0.842 
Sodium (mEq/L) 140.02 (2.92) 139.93 (2.97) 0.690 140.06 (2.86) 140.04 (2.79) 0.941 
Leukocytes (1000/uL) 7.31 (2.45) 7.89 (9.59) 0.410 7.33 (2.44) 7.66 (7.24) 0.558 
Hb A1C 6.57 (1.94) 6.57 (1.9) 0.976 6.57 (1.94) 6.57 (1.82) 0.991 










Ferritin (ng/mL) 195.35 (268.81) 107.49 (149.07) 0.057 195.35 (268.81) 94.01 (99.9) 0.082 
Outcomes 
 
AEO 2020  




(95% CI) ;  
P-Value 
AEO 2020  
N= 5886 (%) 
AEO 2019 
N= 5886 (%) 
Risk Ratio 
(95% CI) ;  
P-Value 




52 (0.88) 229 (3.89) 
0.23 (0.17, 
0.31); <0.001 




991 (16.84) 1583 (26.89) 
0.63 (0.58, 
0.67); <0.001 








€ Propensity score matching was done based on the following variables: age, gender, race, hypertension, diabetes mellitus, chronic lower respiratory disease, chronic kidney disease (CKD), obesity, 
ischemic heart disease, alcohol-related disorders, eosinophilic esophagitis, gastrointestinal hemorrhage, and psychotic disorders. 
